Plain-English translation of NCT05457699 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a treatment approach called multi-site directed radiation therapy (MDRT)—focused radiation aimed at specific areas where cancer has spread—can improve results when added to hormone therapy for men with metastatic prostate cancer that has responded well to initial treatment. The trial will compare men who receive this additional radiation therapy to those who receive standard hormone therapy alone, measuring whether the radiation helps bring cancer markers (PSA levels) down further and helps prevent the cancer from returning.
Even when hormone therapy works well and stops cancer growth, some patients still have detectable cancer markers or small areas of remaining disease. This trial exists to find out whether targeting those remaining spots with focused radiation can eliminate more disease and help men stay cancer-free longer.
You likely qualify if…
You likely don't qualify if…
If you are randomly selected for the experimental group, you will receive focused radiation therapy to areas where cancer has spread, in addition to your ongoing hormone therapy. Your PSA level will be checked at least 3 months after treatment; if it remains high, you may receive a second round of radiation to remaining disease spots. You will be followed over time with regular check-ups and imaging to track how well the treatment is working and whether cancer returns. Those not selected will continue standard hormone therapy alone and may receive standard radiation only if medically necessary.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Canada